Propanc Biopharma Signs MOU with Avance Clinical for PRP Phase 1b First-in-Human Oncology Trial

Australia's regulatory environment is doing tangible work for early-phase oncology programs: Propanc Biopharma has signed a Memorandum of Understanding with Avance Clinical Pty Ltd to support clinical delivery of a Phase 1b First-in-Human (FIH) study of PRP, its lead investigational candidate targeting advanced solid tumors. For clinical operations and regulatory leads at small biotechs, the structure of this partnership illustrates how Australian trial infrastructure can compress early-phase timelines and reduce burn rate simultaneously.

The planned Phase 1b study is designed to evaluate safety, tolerability, pharmacokinetics, immunogenicity, and preliminary clinical activity of PRP in patients with advanced cancer. Avance Clinical, a full-service CRO with more than 30 years of early-phase experience, brings adaptive dose-escalation design and PK/PD-rich study architecture to the program. Notably, Avance's Chief Scientific Officer cited alignment with FDA Project Optimus expectations as a design priority, a signal that dose-optimization considerations are being built into the FIH protocol from the outset, not retrofitted at a later phase.

The Australian operational context is a material factor here. Propanc has maintained its wholly owned subsidiary, Propanc Pty Ltd, in Melbourne since 2007, positioning the company to access the Australian R&D tax rebate of up to 43.5% and the country's comparatively rapid ethics approval pathway. For clinical supply and regulatory affairs teams evaluating FIH geography, those two variables, cash-flow impact and ethics cycle time, directly affect IND-equivalent submission sequencing and investigational product release timelines.

The MOU frames the collaboration as extending beyond FIH execution: both parties have stated intent to support a data-driven transition into Proof-of-Concept and, contingent on emerging data, later-phase development. That framing places CAPA-ready data governance and early alignment on ICH E6(R3) GCP expectations as near-term operational priorities for the joint team.

The FIH study's progression to a formal clinical trial agreement and subsequent ethics submission will serve as the next measurable checkpoint for this program.

Source: Propanc Biopharma via GlobeNewswire, 7 July 2026.